Nimbus Therapeutics: Funding, Investors & Team (Sep 2026)
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Nimbus Therapeutics has raised $230M across 2 funding rounds on record, the most recent an undisclosed round of $125M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nimbus Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Nimbus Therapeutics Funding Rounds
Nimbus Therapeutics raised $105M in an undisclosed round announced in Jul 2021.
1.2 years later, an undisclosed round of $125M was announced in Sep 2022.
Nimbus Therapeutics Founders and Leadership Team
Contact details for the Nimbus Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Nimbus Therapeutics Funding Compared to Other Biotechnology Startups
Nimbus Therapeutics' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nimbus Therapeutics in Biotechnology and Cambridge
Companies Similar to Nimbus Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Nimbus Therapeutics Funding FAQs
What does Nimbus Therapeutics do?
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
How much funding has Nimbus Therapeutics raised?
Nimbus Therapeutics has raised $230M across 2 rounds on record. The most recent is an undisclosed round of $125M announced in Sep 2022.
When did Nimbus Therapeutics last raise funding?
Nimbus Therapeutics' most recent funding round on record is an undisclosed round of $125M, announced in Sep 2022.
Who is the CEO of Nimbus Therapeutics?
Jeb Keiper is listed as CEO at Nimbus Therapeutics.
Where is Nimbus Therapeutics headquartered?
Nimbus Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Nimbus Therapeutics have?
Nimbus Therapeutics is in the 51-100 employee band.
How does Nimbus Therapeutics' funding compare to other Biotechnology startups?
Nimbus Therapeutics' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Nimbus Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nimbus Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.